Kawazoe, Akihito
Shitara, Kohei
Kuboki, Yasutoshi
Bando, Hideaki
Kojima, Takashi
Yoshino, Takayuki
Ohtsu, Atsushi
Ochiai, Atsushi
Togashi, Yosuke
Nishikawa, Hiroyoshi
Doi, Toshihiko
Kuwata, Takeshi
Article History
Received: 27 March 2018
Accepted: 29 May 2018
First Online: 1 June 2018
Compliance with ethical standards
:
: KS has received personal fees from Astellas, Bristol-Myers Squibb, Takeda, Pfizer, Novartis, Abbvie and Yakult; grants and personal fees from Eli Lilly and Ono Pharma; grants from Sumitomo Dainippon Pharma, MSD, Daiichi-Sankyo, Taiho Pharma, and Chugai Pharma. All remaining authors have declared no conflicts of interest. YK has received personal fees from Taiho Pharma, Bayer, and Eli Lilly; grants from Takeda, AstraZeneca, Daiichi-Sankyo, and Incyte. TY has received personal fees from Eli Lilly; grants from GlaxoSmithKline K.K and Nippon Boehringer Ingelheim Co., Ltd. AO has received grants from Bristol-Myers Squibb. YT has received personal fees and grants from Ono Pharma, personal fees from MSD, Chugai Pharmaceutical Co., Ltd, AstraZeneca, Boehringer Ingelheim Japan Inc, Novartis Pharma, and Eli Lilly Japan. HN has received grants from Ono Pharma, Kyowa Hakko Kirin, Sysmex, Taiho Pharma, Zenyaku-kogyo, and Daiichi-Sankyo. TD has received personal fees from Amgen; grants and personal fees from Eli Lilly, Chugai Pharma, Kyowa Hakko Kirin, MSD, and Daiichi Sankyo; grants from Taiho Pharma, Novartis, Merck Serono, Astellas Pharma Janssen, Boehringer Ingelheim, Takeda, Pfizer and Sumitomo Group, Celegene and Bristo Myers Squibb, Abbvie, and Quintiles. TK has received personal fees from Chugai Pharma and grants from government. All remaining authors have declared no conflicts of interest.
: All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1964 and later versions.
: Informed consent or substitute was obtained from all patients for being included in the study.